ARCHIVES

NCCS Names 7 To Board; FDA Approves Warning Labels for Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 29 No. 03 | January 17, 2003

Download PDF Visit The Full Archive

Related Articles

ODAC Unanimously Rejects Melblez, Citing Lower Survival

May 17, 2013

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

ASCO Ends Early Distribution Of Abstracts To Halt “ASCO Effect” On Stock Market

January 24, 2003

Yates Named DRCCA AD To Head Centers, CCOP, Organ Sites: CCOP Workshops Listed

February 26, 1982

Zerhouni forms steering committee; Olden to retire.

August 1, 2003

Hatch Hearing Turns Up Few New Deficiencies In NCI Contract Management; DeVita Blasted On Strauss

June 5, 1981